Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 15, Pages 10666-10679Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00713
Keywords
-
Categories
Ask authors/readers for more resources
Discovery of compound 38 (pemigatinib), a highly potent and selective inhibitor of FGFR1, FGFR2, and FGFR3, has led to accelerated approval by the FDA for the treatment of cholangiocarcinoma with FGFR alterations. Ongoing clinical trials are evaluating pemigatinib in patients with FGFR alterations.
Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the discovery of compound 38 (INCB054828, pemigatinib), a highly potent and selective inhibitor of FGFR1, FGFR2, and FGFR3 with excellent physiochemical properties and pharmacokinetic profiles. Pemigatinib has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Additional clinical trials are ongoing to evaluate pemigatinib in patients with FGFR alterations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available